Pediatric Drugs Market Report 2026

The pediatric drugs market size has grown rapidly in recent years. It will grow from $179.43 billion in 2025 to $205.6 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to high prevalence of pediatric infectious diseases, expansion of vaccination and treatment programs, growth in pediatric hospital infrastructure, improved child healthcare access, increased awareness of pediatric medication safety.

The pediatric drugs market size is expected to see rapid growth in the next few years. It will grow to $352.69 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising pediatric population in emerging markets, growth in childhood chronic conditions, increasing investment in pediatric drug research, expansion of child-focused healthcare policies, rising demand for safer pediatric therapies. Major trends in the forecast period include increasing demand for age-appropriate drug formulations, growing focus on pediatric-specific dosage accuracy, rising use of liquid and chewable pediatric medicines, expansion of pediatric chronic disease management, increased regulatory emphasis on pediatric clinical trials.

The rising incidence of preterm births is poised to drive expansion in the pediatric drugs market. Preterm births involve infants delivered before 37 weeks of gestation, short of the standard 40-week term. This increase stems from factors like advancing maternal age, lifestyle factors, underlying health issues, multiple gestations, and insufficient prenatal care. Pediatric drugs play a vital role in supporting the health and growth of these infants by providing specialized therapies for issues like respiratory distress, infections, and nutritional deficiencies. For instance, in 2023, Tommy’s - a UK charity - reported that premature live births in England and Wales climbed to 8.1%, from 7.9% in 2022, affecting over 48,000 babies that year. Thus, the surge in preterm births is fueling growth in the pediatric drugs market.

Major companies in the pediatric drugs market are increasingly introducing long-acting monoclonal antibodies for infectious diseases in infants, such as extended half-life RSV prevention therapies. A long-acting monoclonal antibody is a biologic engineered to stay in the bloodstream longer, delivering ongoing protection with fewer administrations. For example, in June 2025, Merck - a U.S.-based pharmaceutical firm - gained FDA approval for clesrovimab (Enflonsia), a fully human monoclonal antibody that prevents respiratory syncytial virus (RSV) in infants. Clesrovimab boasts an extended half-life via improved Fc receptor binding, provides lasting protection through the first RSV season, and requires just one intramuscular dose.

In January 2023, Ipsen, a biopharmaceutical firm based in France, bought Albireo Pharma for about $952 million. Through this deal, Ipsen seeks to grow its footprint in the pediatric market by using Albireo’s flagship drug, odevixibat (Bylvay), a treatment for progressive familial intrahepatic cholestasis (PFIC), to bolster its rare-disease offerings and fuel expansion in pediatric therapies. Albireo Pharma, a U.S.-based biopharmaceutical company, focuses on creating therapies for rare pediatric liver conditions.

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila.

North America was the largest region in the pediatric drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pediatric drugs market by increasing the cost of imported APIs and child specific excipients used in formulation development and manufacturing. These impacts are most visible in oral and parenteral pediatric drugs supplied through hospital and retail pharmacy channels. Developing regions have been particularly affected due to higher dependence on imported pediatric grade pharmaceutical inputs. Rising tariff related expenses have influenced production costs, pricing strategies, and procurement planning for pediatric medicines. Positively, tariffs have encouraged domestic manufacturing, expanded localized pediatric drug production, and strengthened long term supply security.

The pediatric drugs market research report is one of a series of new reports that provides pediatric drugs market statistics, including pediatric drugs industry global market size, regional shares, competitors with a pediatric drugs market share, detailed pediatric drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric drugs industry. This pediatric drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric medications consist of drugs specially formulated, dosed, or approved for infants, children, and adolescents. They target a range of health conditions in young patients, accounting for their distinct physiological and metabolic variations compared to adults.

The primary categories of pediatric drugs include those for respiratory disorders, autoimmune disorders, gastrointestinal issues, and cardiovascular conditions. Respiratory disorder drugs target breathing difficulties in children, like asthma, cystic fibrosis, and RSV. They come in forms delivered via oral, topical, parenteral, or alternative routes, and reach patients through hospital pharmacies, retail pharmacies, online pharmacies, and various other channels. These medications serve end-users such as hospitals, specialty clinics, homecare settings, and additional healthcare environments.

The pediatric drugs market consists of sales of antibiotics, vaccines, pediatric pain relief, respiratory medications, antihistamines, and pediatric dermatology products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.